ReviewNature cancer2026
Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment.
Review in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oncolytic viruses enhance CAR-T activity for the treatment of pediatric diffuse midline gliomas.Molecular therapy. Oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Solid tumors are sustained by profoundly immunosuppressive tumor microenvironments (TMEs) that underlie resistance to immunotherapy. Engineered oncolytic viruses and cytokine-based gene therapies can reprogram the TME, converting 'cold' tumors into immune-responsive states and amplifying antitumor immunity. Several agents have achieved regulatory approval, and clinical studies demonstrate that even limited dosing can induce durable changes in immune infiltration and cytokine signaling. Yet consistent and lasting clinical responses remain elusive. Here, we synthesize translational insights from recent trials and highlight emerging strategies to overcome barriers and enhance the therapeutic impact of these TME-modulating biologics.
Indexed as
Identifiers
42032342What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.